The addition of gemtuzumab ozogamicin to induction chemotherapy in AML reduces relapse and improves survival in the majority of patients of all ages: the AML15 and 16 trial experience [Abstract]

Burnett, Alan Kenneth, Freeman, S., Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Hunter, A. E., Milligan, D. W., Kell, W. J., Wheatley, K., Yin, J. A. L., Ali, S., Kjeldsen, L., Goldstone, A. H., Bowen, D and Russell, N. H. 2012. The addition of gemtuzumab ozogamicin to induction chemotherapy in AML reduces relapse and improves survival in the majority of patients of all ages: the AML15 and 16 trial experience [Abstract]. British Journal of Haematology 157 (S1) , p. 1. 10.1111/j.1365-2141.2012.09071.x

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Additional Information:	Special Issue: Abstracts of the 52nd Annual Scientific Meeting of the British Society for Haematology, 16-18 April 2012, Glasgow, UK
Publisher:	Wiley-Blackwell
ISSN:	0007-1048
Last Modified:	24 Oct 2022 11:56
URI:	https://orca.cardiff.ac.uk/id/eprint/49792

Actions (repository staff only)

Edit Item